Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367830 | 1.00 | TRPV1 (0.52) | TRPV1HSD11B1TRPA1MALT1PDE4A | |
| SCHEMBL1367831 | 1.00 | TRPV1 (0.52) | TRPV1HSD11B1TRPA1MALT1PDE4A | |
| SCHEMBL1366697 | 0.88 | TRPV1 (0.43) | TRPV1HSD11B1MALT1 | |
| SCHEMBL1368769 | 0.87 | HSD11B1 (0.47) | TRPV1HSD11B1 | |
| SCHEMBL8296999 | 0.77 | TRPV1 (0.53) | TRPV1HSD11B1TRPA1 | |
| SCHEMBL2762077 | 0.73 | DRD2 (0.39) | — | |
| SCHEMBL2762076 | 0.73 | DRD2 (0.39) | — | |
| SCHEMBL915459 | 0.73 | DRD2 (0.39) | — | |
| SCHEMBL2688588 | 0.72 | TRPV1 (0.36) | TRPV1PDE4APDE4CPDE4D | |
| SCHEMBL1367834 | 0.71 | TRPV1 (0.77) | TRPV1HSD11B1TRPA1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
| US-7998982-B2 | Amide derivatives as TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2185538-A2 | TETRAHYDROPYRIDINE CARBOXAMIDE DERIVATIVES AS TRPVL ANTAGONISTS | Abbott Laboratories (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090062345-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2009023539-A2 | TETRAHYDROPYRIDINE CARBOXAMIDE DERIVATIVES AS TRPVL ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062345-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885HSD11B1 3218/4885TRPA1 3/4885 |
| US-20110288129-A1 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPA1 | TRPV1 1/4885HSD11B1 3218/4885TRPA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.